Literature DB >> 2248432

Arterial metabolism of lipoproteins in relation to atherogenesis.

D Steinberg1.   

Abstract

In this short review we have concentrated on the ways in which modification of LDL structure may account for foam cell formation. We have presented in vivo evidence as well as in vitro evidence supporting the proposition that modification of native LDL is a prerequisite for foam cell formation and atherogenesis. Actually, oxidized LDL can contribute to atherogenesis in other ways as well. Oxidized LDL is chemotactic for circulating monocytes, yet inhibits the motility of the tissue macrophage as shown by Quinn et al. Also, oxidized LDL is cytotoxic as discussed above and this could play a crucial role in the transition from the fatty streak lesion to the clinically more consequential fibrous plaque and complicated lesion. If further research supports the importance of LDL modification in atherogenesis, a whole new array of possibilities opens itself to us for intervention. Anything that interferes with the relevant modifications of the LDL structure would presumably be additive to interventions lowering the plasma concentration of LDL. At the moment, the only such intervention that appears to be feasible is prevention of LDL oxidation. Possibly we may find ways to interfere with immune mechanisms that are involved in some patients; conceivably we might be able to interfere with the aggregation of LDL with itself or with other complexes in the artery wall that appear also to favor initiation of the atherogenic process.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2248432     DOI: 10.1111/j.1749-6632.1990.tb42284.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

Review 1.  Role of oxidized low density lipoprotein in atherogenesis.

Authors:  J L Witztum; D Steinberg
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

2.  Particulate matter promotes in vitro receptor-recognizable low-density lipoprotein oxidation and dysfunction of lipid receptors.

Authors:  Natalia Manzano-León; Jaime Mas-Oliva; Laura Sevilla-Tapia; Rocío Morales-Bárcenas; Jesús Serrano; Marie S O Neill; Claudia M García-Cuellar; Raúl Quintana; Inés Vázquez-López; Alvaro R Osornio-Vargas
Journal:  J Biochem Mol Toxicol       Date:  2013-01-07       Impact factor: 3.642

3.  Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects.

Authors:  S Nozaki; H Kashiwagi; S Yamashita; T Nakagawa; B Kostner; Y Tomiyama; A Nakata; M Ishigami; J Miyagawa; K Kameda-Takemura
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

4.  Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphatidylserine.

Authors:  G R Sambrano; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

5.  Effect of a novel insulinotropic agent, succinic acid monoethyl ester, on lipids and lipoproteins levels in rats with streptozotocin-nicotinamide-induced type 2 diabetes.

Authors:  Ramalingam Saravanan; Leelavinothan Pari
Journal:  J Biosci       Date:  2006-12       Impact factor: 1.826

6.  Normal human IgG prevents endothelial cell activation induced by TNFalpha and oxidized low-density lipoprotein atherogenic stimuli.

Authors:  N Ronda; F Bernini; R Giacosa; R Gatti; N Baldini; C Buzio; G Orlandini
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

7.  Recognition of oxidatively damaged erythrocytes by a macrophage receptor with specificity for oxidized low density lipoprotein.

Authors:  G R Sambrano; S Parthasarathy; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

8.  A macrophage receptor for oxidized low density lipoprotein distinct from the receptor for acetyl low density lipoprotein: partial purification and role in recognition of oxidatively damaged cells.

Authors:  E Ottnad; S Parthasarathy; G R Sambrano; M P Ramprasad; O Quehenberger; N Kondratenko; S Green; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.

Authors:  Maria Vinaixa; Miguel Angel Rodriguez; Sara Samino; Marta Díaz; Antoni Beltran; Roger Mallol; Cinta Bladé; Lourdes Ibañez; Xavier Correig; Oscar Yanes
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

Review 10.  Angiotensin II, Hypercholesterolemia, and Vascular Smooth Muscle Cells: A Perfect Trio for Vascular Pathology.

Authors:  Amanda St Paul; Cali B Corbett; Rachael Okune; Michael V Autieri
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.